Literature DB >> 22936740

Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens.

Davide Bedognetti, Filippo Ansaldi, Elisa Zanardi, Paolo Durando, Mario Roberto Sertoli, Carlotta Massucco, Enrico Balleari, Omar Racchi, Gabriele Zoppoli, Andrea Orsi, Cristiano Alicino, Giancarlo Icardi, Francesco M Marincola, Simonetta Zupo, Manlio Ferrarini, Andrea De Maria.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22936740      PMCID： PMC3433097          DOI： 10.1182/blood-2012-06-438689

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

Authors:  Davide Bedognetti; Gabriele Zoppoli; Carlotta Massucco; Elisa Zanardi; Simonetta Zupo; Andrea Bruzzone; Mario Roberto Sertoli; Enrico Balleari; Omar Racchi; Marco Messina; Graziano Caltabiano; Giancarlo Icardi; Paolo Durando; Francesco M Marincola; Francesco Boccardo; Manlio Ferrarini; Filippo Ansaldi; Andrea De Maria
Journal:  J Immunol       Date:  2011-04-15       Impact factor: 5.422

2.  Maintenance of the plasma cell pool is independent of memory B cells.

Authors:  Anupama Ahuja; Shannon M Anderson; Ashraf Khalil; Mark J Shlomchik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-13       Impact factor: 11.205

3.  Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment.

Authors:  Olav Erich Yri; Dag Torfoss; Olav Hungnes; Anne Tierens; Kristian Waalen; Tone Nordøy; Susanne Dudman; Anette Kilander; Karin Fahl Wader; Bjørn Ostenstad; Roald Ekanger; Peter Meyer; Arne Kolstad
Journal:  Blood       Date:  2011-11-04       Impact factor: 22.113

4.  Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP.

Authors:  Tohru Takata; Junji Suzumiya; Takahiko Ishikawa; Yasushi Takamatsu; Hideyuki Ikematsu; Kazuo Tamura
Journal:  J Clin Exp Hematop       Date:  2009-05

5.  The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells.

Authors:  Maria Mamani-Matsuda; Antonio Cosma; Sandra Weller; Ahmad Faili; Caroline Staib; Loïc Garçon; Olivier Hermine; Odile Beyne-Rauzy; Claire Fieschi; Jacques-Olivier Pers; Nina Arakelyan; Bruno Varet; Alain Sauvanet; Anne Berger; François Paye; Jean-Marie Andrieu; Marc Michel; Bertrand Godeau; Pierre Buffet; Claude-Agnès Reynaud; Jean-Claude Weill
Journal:  Blood       Date:  2008-03-03       Impact factor: 22.113
  5 in total
  9 in total

1.  Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies.

Authors:  Yuichiro Ide; Yutaka Imamura; Satoko Ohfuji; Wakaba Fukushima; Saburo Ide; Chiyo Tsutsumi; Masahisa Koga; Kazuhiro Maeda; Yoshio Hirota
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review.

Authors:  Vanessa Piechotta; Sibylle C Mellinghoff; Caroline Hirsch; Alice Brinkmann; Claire Iannizzi; Nina Kreuzberger; Anne Adams; Ina Monsef; Jannik Stemler; Oliver A Cornely; Paul J Bröckelmann; Nicole Skoetz
Journal:  Blood Cancer J       Date:  2022-05-31       Impact factor: 9.812

3.  Influenza Vaccination Documentation Rates During the First Year After Diagnosis of Diffuse Large B Cell Lymphoma.

Authors:  Andres Chang; Jackelyn B Payne; Pamela B Allen; Jean L Koff; Rafi Ahmed; Christopher R Flowers; Robert A Bednarczyk
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-01-02

Review 4.  Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.

Authors:  Michael Grever; Leslie Andritsos; Versha Banerji; Jacqueline C Barrientos; Seema Bhat; James S Blachly; Timothy Call; Matthew Cross; Claire Dearden; Judit Demeter; Sasha Dietrich; Brunangelo Falini; Francesco Forconi; Douglas E Gladstone; Alessandro Gozzetti; Sunil Iyengar; James B Johnston; Gunnar Juliusson; Eric Kraut; Robert J Kreitman; Francesco Lauria; Gerard Lozanski; Sameer A Parikh; Jae Park; Aaron Polliack; Farhad Ravandi; Tadeusz Robak; Kerry A Rogers; Alan Saven; John F Seymour; Tamar Tadmor; Martin S Tallman; Constantine S Tam; Enrico Tiacci; Xavier Troussard; Clive Zent; Thorsten Zenz; Pier Luigi Zinzani; Bernhard Wörmann
Journal:  Leukemia       Date:  2021-05-04       Impact factor: 11.528

5.  Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM).

Authors:  P Pedrazzoli; F Baldanti; I Donatelli; M R Castrucci; F Puglisi; N Silvestris; S Cinieri
Journal:  Ann Oncol       Date:  2014-03-11       Impact factor: 32.976

Review 6.  Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy.

Authors:  Nina M Bemben; Melody L Berg
Journal:  Pharmacotherapy       Date:  2022-02-18       Impact factor: 6.251

7.  Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients.

Authors:  Abi Vijenthira; Inna Gong; Stephen D Betschel; Matthew Cheung; Lisa K Hicks
Journal:  Blood Adv       Date:  2021-06-21

8.  Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment.

Authors:  Ariella Tvito; Aaron Ronson; Renan Ghosheh; Mira Kharit; Jakob Ashkenazi; Sophie Magen; Ellen Broide; Emmanuel Benayoun; Jacob M Rowe; Yishai Ofran; Chezi Ganzel
Journal:  Exp Hematol       Date:  2021-12-22       Impact factor: 3.084

9.  Influenza Vaccination Rates Among Patients With a History of Cancer: Analysis of the National Health Interview Survey.

Authors:  Andres Chang; Mallory K Ellingson; Christopher R Flowers; Robert A Bednarczyk
Journal:  Open Forum Infect Dis       Date:  2021-04-20       Impact factor: 3.835
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.